Targeting thrombin - Rational drug design from natural mechanisms

Trends in Pharmacological Sciences

Volumn 24, Issue 11, 2003, Pages 589-595

  Huntington, James A ^a   Baglin, Trevor P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HEPARIN COFACTOR II; HEPARIN DERIVATIVE; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; RECOMBINANT HIRUDIN; RECOMBINANT THROMBOMODULIN; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; VASOFLUX; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 0242384136     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.09.002     Document Type: Review

References (71)

1. Francis C.W., et al. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J. Lab. Clin. Med. 102:1983;220-230.
2. Liu C.Y., et al. The binding of thrombin by fibrin. J. Biol. Chem. 254:1979;10421-10425.
3. Becker D.L., et al. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J. Biol. Chem. 274:1999;6226-6233.
4. Ofosu F.A. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfus. Apheresis Sci. 28:2003;265-268.
5. Bode W., et al. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8:1989;3467-3475.
6. Huntington J.A., Esmon C.T. The molecular basis of thrombin allostery revealed by a 1.8 a structure of the "Slow" form. Structure (Camb). 11:2003;469-479.
7. Stubbs M.T., Bode W. The clot thickens: clues provided by thrombin structure. Trends Biochem. Sci. 20:1995;23-28.
8. Fuentes-Prior P., et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 404:2000;518-525.
9. Esmon C.T. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 9:1995;946-955.
10. Sheehan J.P., Sadler J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5518-5522.
11. Hall S.W., et al. Identification of critical residues on thrombin mediating its interaction with fibrin. Thromb. Haemost. 86:2001;1466-1474.
12. Krishnan R., et al. Structure of the Ser195Ala mutant of human alpha-thrombin complexed with fibrinopeptide A(7-16): evidence for residual catalytic activity. Acta Crystallogr. D Biol. Crystallogr. 56:2000;406-410.
13. Ayala Y.M., et al. Molecular mapping of thrombin-receptor interactions. Proteins. 45:2001;107-116.
14. Myles T., et al. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. J. Biol. Chem. 273:1998;31203-31208.
15. Von Dem Borne P.A., et al. Effect of heparin on the activation of factor XI by fibrin-bound thrombin. Thromb. Haemost. 76:1996;347-353.
16. Philippou H., et al. Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate. J. Biol. Chem. 10:2003;1074.
17. Stone S.R., Le Bonniec B.F. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease. J. Mol. Biol. 265:1997;344-362.
18. Dharmawardana K.R., et al. Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments. J. Biol. Chem. 274:1999;18635-18643.
19. Myles T., et al. Structural requirements for the activation of human factor VIII by thrombin. Blood. 100:2002;2820-2826.
20. Esmon C.T., Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J. Biol. Chem. 271:1996;13882-13887.
21. Hall S.W., et al. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J. Biol. Chem. 274:1999;25510-25516.
22. He X., et al. Influence of arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry. 36:1997;8969-8976.
23. Baglin T.P., et al. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11079-11084.
24. Sadler J.E. Thrombomodulin structure and function. Thromb. Haemost. 78:1997;392-395.
25. Yang L., Rezaie A.R. The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C. J. Biol. Chem. 278:2003;10484-10490.
26. Khorchidi S., et al. ART-123 Asahi Kasei. Curr. Opin. Investig. Drugs. 3:2002;1196-1198.
27. Huntington J.A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1:2003;1535-1549.
28. Jin L., et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14683-14688.
29. Olson S.T., Bjork I. Role of protein conformational changes, surface approximation and protein cofactors in heparin-accelerated antithrombin- proteinase reactions. Adv. Exp. Med. Biol. 313:1992;155-165.
30. Olson S.T., Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J. Biol. Chem. 266:1991;6353-6364.
31. Olson S.T., et al. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J. Biol. Chem. 266:1991;6342-6352.
32. Liaw P.C., et al. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II. J. Biol. Chem. 274:1999;27597-27604.
33. Salem H.H., Thompson E.A. The role of heparin cofactor II in the modulation of hemostasis. Dev. Biol. Stand. 67:1987;67-72.
34. Simioni P. The molecular genetics of familial venous thrombosis. Baillieres. Best Pract. Res. Clin. Haematol. 12:1999;479-503.
35. Ishiguro K., et al. Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Invest. 106:2000;873-878.
36. Tollefsen D.M. Heparin cofactor II deficiency. Arch. Pathol. Lab. Med. 126:2002;1394-1400.
37. He L., et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J. Clin. Invest. 109:2002;213-219.
38. Tollefsen D.M. Heparin cofactor II. Adv. Exp. Med. Biol. 425:1997;35-44.
39. Weitz J.I. Low-molecular-weight heparins. New Engl. J. Med. 337:1997;688-698.
40. Kelton J.G. Heparin-induced thrombocytopenia: an overview. Blood Rev. 16:2002;77-80.
41. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol. 121:2003;535-555.
42. Weitz J.I., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86:1990;385-391.
43. Liaw P.C., et al. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin. J. Biol. Chem. 276:2001;20959-20965.
44. Becker D.L., et al. Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv. Exp. Med. Biol. 425:1997;55-66.
45. Meuleman D.G. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis. 22:1992;58-65.
46. Weitz J.I., et al. Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 99:1999;682-689.
47. Peters R.J., et al. Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). Am. Heart J. 142:2001;237-243.
48. Anderson J.A., et al. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J. Biol. Chem. 276:2001;9755-9761.
49. Dettori A.G., et al. Pharmacological activity of a low molecular weight dermatan sulfate (desmin) in healthy volunteers. Semin. Thromb. Hemost. 20:1994;259-265.
50. Barbanti M., et al. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis-evidence for an anticoagulant-independent mechanism. Thromb. Haemost. 69:1993;147-151.
51. Petitou M., et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin. Thromb. Hemost. 28:2002;393-402.
52. Petitou M., et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature. 398:1999;417-422.
53. Berry L.R., et al. Inhibition of fibrin-bound thrombin by a covalent antithrombin-heparin complex. J. Biochem. (Tokyo). 132:2002;167-176.
54. Markwardt F. Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Semin. Thromb. Hemost. 27:2001;523-530.
55. Rydel T.J., et al. Refined structure of the hirudin-thrombin complex. J. Mol. Biol. 221:1991;583-601.
56. Qiu X., et al. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J. Biol. Chem. 268:1993;20318-20326.
57. Richardson J.L., et al. Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor. EMBO J. 19:2000;5650-5660.
58. van de Locht A., et al. Two heads are better than one: crystal structure of the insect derived double domain Kazal inhibitor rhodniin in complex with thrombin. EMBO J. 14:1995;5149-5157.
59. van de Locht A., et al. The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J. 15:1996;6011-6017.
60. Fuentes-Prior P., et al. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11845-11850.
61. Lombardi A., et al. From natural to synthetic multisite thrombin inhibitors. Biopolymers. 51:1999;19-39.
62. Markwardt F. Hirudin as alternative anticoagulant-a historical review. Semin. Thromb. Hemost. 28:2002;405-414.
63. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 25:1986;4622-4628.
64. Salzet M. Leech thrombin inhibitors. Curr. Pharm. Des. 8:2002;493-503.
65. Bates S.M., Weitz J.I. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am. J. Cardiol. 82:1998;12P-18P.
66. Danilewicz J.C., et al. Design of selective thrombin inhibitors based on the (R)-Phe-Pro-Arg sequence. J. Med. Chem. 45:2002;2432-2453.
67. Marque P.E., et al. The role of Glu(192) in the allosteric control of the S(2)′ and S(3)′ subsites of thrombin. J. Biol. Chem. 275:2000;809-816.
68. Maimone M.M., Tollefsen D.M. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J. Biol. Chem. 265:1990;18263-18271.
69. Gonze M.D., et al. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation. 101:2000;2658-2661.
70. Lee Y., et al. Oral delivery of new heparin derivatives in rats. Pharm. Res. 17:2000;1259-1264.
71. Rezaie A.R., Olson S.T. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies. Biochemistry. 39:2000;12083-12090.